|
|
| | SGI 7079 Basic information |
| Product Name: | SGI 7079 | | Synonyms: | 3-[2-[[3-Fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]benzeneacetonitrile;SGI 7079;SGI-7079 /SGI7079;2-(3-(2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)acetonitrile;SGI-7079;SGI 7079;SGI7079;CS-2333;Benzeneacetonitrile, 3-[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-;Tyro3,inhibit,SGI 7079,Inhibitor,Axl,SGI-7079,Mer,TAM Receptor,SGI7079 | | CAS: | 1239875-86-5 | | MF: | C26H26FN7 | | MW: | 455.53 | | EINECS: | | | Product Categories: | | | Mol File: | 1239875-86-5.mol |  |
| | SGI 7079 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS(pH 7.2) (1:3): 0.25 mg/ml | | form | A crystalline solid |
| | SGI 7079 Usage And Synthesis |
| Description | SGI-7079 is an inhibitor of the receptor tyrosine kinase Axl. It inhibits proliferation of inflammatory breast cancer cells (IC50s = 0.43 and 0.15 μM for SUM149 and KPL-4 cells, respectively), decreases invasion, and halts the cell cycle in the G1 phase. SGI-7079 synergistically increases the potency of erlotinib on EGFR inhibition. In a mouse xenograft model of non-small cell lung cancer, SGI-7079 dose-dependently inhibits tumor growth, an effect that is greater when used in combination with erlotinib. | | Uses | 3-[2-[[3-Fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]benzeneacetonitrile is an anticancer agent and a selective Axl inhibitor. |
| | SGI 7079 Preparation Products And Raw materials |
|